Alumis Inc.
Moat Score — Alumis Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Alumis holds patents on its specific TYK2 inhibitor molecule and other pipeline candidates, but is pursuing a mechanism already validated and commercialized by a larger competitor, limiting the degree of scientific novelty underlying its intellectual property position. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage company with no commercial manufacturing scale, Alumis has no cost advantage versus larger, already-commercial competitors like Bristol Myers Squibb. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products, Alumis has no current pricing power, and any future pricing would be constrained by the need to compete against or differentiate from the already-launched Sotyktu. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products do not exhibit network effects between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no marketed products, there are no existing prescriber or patient relationships creating switching costs for Alumis specifically. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The autoimmune/inflammatory disease therapeutic market is enormous and supports numerous large, well-funded competitors, offering little efficient-scale protection to a single clinical-stage entrant. |